■最近的报道表明,2019年冠状病毒病(COVID-19)感染即使在没有临床症状的情况下也会导致肺炎,而COVID-19相关的肺部炎症会持续导致长期纤维化。这项单中心研究利用标准化的免疫学检测来确定来自COVID-19血清阳性供体的肺,指示过去的COVID-19感染,可安全用于临床移植。
该研究包括90例连续的肺移植手术,其中包括对过去的COVID-19感染的供体血清学检测。捐赠者对活动性COVID-19感染呈阴性,符合用于肺移植的机构标准。比较了有和没有过去感染过COVID-19的血清学证据的供体之间肺移植受者的结局。
■与没有血清学证据的供体相比,从供体获得的肺受体的移植后存活率没有显着差异。此外,原发性移植物功能障碍3级发生率或其他移植后临床参数没有显着差异,比如手术时间,缺血时间,体外膜氧合的使用,重症监护室逗留,住院。
■我们的研究结果表明,来自COVID-19血清阳性供体的肺部,但非活动性COVID-19感染对于移植是安全可行的,移植后结果与COVID-19抗体阴性的供体相当。这项研究支持利用患有历史COVID-19感染的捐赠者的肺,只要他们符合目前的移植标准,可能解决与使用此类器官有关的问题。
UNASSIGNED: Recent reports have suggested that coronavirus disease 2019 (COVID-19) infection can cause pneumonitis even in the absence of clinical symptoms and COVID-19 associated pulmonary inflammation can persist resulting in long-term fibrosis. This single-center study utilized standardized immunological testing to determine whether lungs from COVID-19 seropositive donors, indicative of past COVID-19 infection, can be safely used for clinical transplantation.
UNASSIGNED: The study included 90 consecutive lung transplant procedures incorporating donor serological testing for past COVID-19 infection. Donors were negative for active COVID-19 infection and met institutional criteria to be used for lung transplantation. The outcomes of lung transplant recipients were compared between donors with and without serological evidence of past COVID-19 infection.
UNASSIGNED: No significant difference was found in post-transplant survival rates between recipients of lungs obtained from donors with serological evidence compared to those without. Additionally, there were no significant differences in primary graft dysfunction grade 3 rates or other post-transplant clinical parameters, such as operative time, ischemic time, extracorporeal membrane oxygenation use, intensive care unit stay, and hospital stay.
UNASSIGNED: Our findings suggest that lungs from COVID-19 seropositive donors, but not active COVID-19 infection are safe and feasible for transplantation, yielding comparable post-transplant outcomes to donors who are negative COVID-19 antibodies. This study supports the utilization of lungs from donors with historic COVID-19 infection as long as they meet current transplant criteria, potentially addressing the concerns related to the use of such organs.